Literature DB >> 20665750

Development and validation of the brief-satisfaction with appearance scale for systemic sclerosis.

Lisa R Jewett1, Marie Hudson, Jennifer A Haythornthwaite, Leslie Heinberg, Fredrick M Wigley, Murray Baron, Brett D Thombs.   

Abstract

OBJECTIVE: Body image concerns are understudied in systemic sclerosis (SSc; scleroderma). The objective was to develop and cross-validate a brief version of the Satisfaction with Appearance Scale (SWAP) in order to reduce item redundancy, increase SSc relevancy, and improve the feasibility of body image assessment in SSc.
METHODS: Female patients with SSc in a development sample (Johns Hopkins Scleroderma Center) and a validation sample (Canadian Scleroderma Research Group Registry) completed the 14-item SWAP. Items for the 6-item Brief-SWAP were selected based on theoretical considerations and psychometric data from the development sample. In both samples, internal consistency reliability, convergent validity, and the hypothesized 2-factor structure (perceived social impact and subjective dissatisfaction) were compared between the Brief-SWAP and SWAP.
RESULTS: Two hundred seventeen women from the development sample and 654 women from the validation sample completed the SWAP. Cronbach's alpha for the Brief-SWAP was 0.82 in both samples, compared with 0.90 and 0.91 for the full SWAP. Correlations between the Brief-SWAP and SWAP were 0.94 and 0.95 in the development and validation samples, respectively. All correlations of the Brief-SWAP and SWAP with measures of convergent validity were substantively equal with no statistically significant differences in either sample. Based on confirmatory factor analysis, model fit for the Brief-SWAP was good in the development (χ2 [4]=9.0, comparative fit index [CFI]=0.99, Tucker-Lewis Index [TLI]=0.99, root mean square error of approximation [RMSEA]=0.07) and validation samples (χ2 [4]=19.5, CFI=0.99, TLI=0.99, RMSEA=0.08) and better than for the SWAP.
CONCLUSION: The Brief-SWAP is a reliable and valid measure of body image dissatisfaction and social discomfort in SSc that is shorter and more feasibly implemented than the SWAP.
Copyright © 2010 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2010        PMID: 20665750     DOI: 10.1002/acr.20307

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  13 in total

1.  Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study.

Authors:  Sarah D Mills; Rina S Fox; Erin L Merz; Philip J Clements; Suzanne Kafaja; Vanessa L Malcarne; Daniel E Furst; Dinesh Khanna
Journal:  J Rheumatol       Date:  2015-06-01       Impact factor: 4.666

2.  New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN).

Authors:  Brett D Thombs; Lisa R Jewett; Shervin Assassi; Murray Baron; Susan J Bartlett; Angela Costa Maia; Ghassan El-Baalbaki; Daniel E Furst; Karen Gottesman; Jennifer A Haythornthwaite; Marie Hudson; Ann Impens; Annett Korner; Catarina Leite; Maureen D Mayes; Vanessa L Malcarne; Sarosh J Motivala; Luc Mouthon; Warren R Nielson; Diane Plante; Serge Poiraudeau; Janet L Poole; Janet Pope; Maureen Sauve; Russell J Steele; Maria E Suarez-Almazor; Suzanne Taillefer; Cornelia H van den Ende; Erin Arthurs; Marielle Bassel; Vanessa Delisle; Katherine Milette; Allison Leavens; Ilya Razykov; Dinesh Khanna
Journal:  Clin Exp Rheumatol       Date:  2012-05-29       Impact factor: 4.473

3.  Factors related to alexithymia in patients with systemic sclerosis: a tight relationship with facial image dissatisfaction.

Authors:  Fabio Basta; Domenico Paolo Emanuele Margiotta; Carmen Mazzuca; Veronica Batani; Giulio Dolcini; Patrizio Moras; Marta Vadacca; Antonella Afeltra
Journal:  Rheumatol Int       Date:  2018-11-29       Impact factor: 2.631

4.  Validation of the Social Interaction Anxiety Scale in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort study.

Authors:  Shadi Gholizadeh; Linda Kwakkenbos; Marie-Eve Carrier; Sarah D Mills; Rina S Fox; Lisa R Jewett; Karen Gottesman; Scott Roesch; Brett D Thombs; Vanessa L Malcarne
Journal:  J Scleroderma Relat Disord       Date:  2017-10-24

Review 5.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

6.  Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life Study.

Authors:  Rina S Fox; Sarah D Mills; Shadi Gholizadeh; Erin L Merz; Scott C Roesch; Philip J Clements; Suzanne Kafaja; Dinesh Khanna; Daniel E Furst; Vanessa L Malcarne
Journal:  J Scleroderma Relat Disord       Date:  2019-12-22

7.  Development and Validation of the Body Concealment Scale for Scleroderma.

Authors:  Lisa R Jewett; Vanessa L Malcarne; Linda Kwakkenbos; Diana Harcourt; Nichola Rumsey; Annett Körner; Russell J Steele; Marie Hudson; Murray Baron; Jennifer A Haythornthwaite; Leslie Heinberg; Fredrick M Wigley; Brett D Thombs
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-08       Impact factor: 4.794

8.  Sociodemographic and disease correlates of body image distress among patients with systemic sclerosis.

Authors:  Lisa R Jewett; Marie Hudson; Vanessa L Malcarne; Murray Baron; Brett D Thombs
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

9.  Sexual activity and impairment in women with systemic sclerosis compared to women from a general population sample.

Authors:  Brooke Levis; Andrea Burri; Marie Hudson; Murray Baron; Brett D Thombs
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

10.  The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context.

Authors:  Linda Kwakkenbos; Lisa R Jewett; Murray Baron; Susan J Bartlett; Dan Furst; Karen Gottesman; Dinesh Khanna; Vanessa L Malcarne; Maureen D Mayes; Luc Mouthon; Serge Poiraudeau; Maureen Sauve; Warren R Nielson; Janet L Poole; Shervin Assassi; Isabelle Boutron; Carolyn Ells; Cornelia Hm van den Ende; Marie Hudson; Ann Impens; Annett Körner; Catarina Leite; Angela Costa Maia; Cindy Mendelson; Janet Pope; Russell J Steele; Maria E Suarez-Almazor; Sara Ahmed; Stephanie Coronado-Montoya; Vanessa C Delisle; Shadi Gholizadeh; Yeona Jang; Brooke Levis; Katherine Milette; Sarah D Mills; Ilya Razykov; Rina S Fox; Brett D Thombs
Journal:  BMJ Open       Date:  2013-08-07       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.